The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma

Murphy, Kevin R.; Nelson, Harold S.; Parasuraman, Bhash; Boggs, Robert; Miller, Christopher J.; O'Dowd, L.

doi:10.1185/030079908x273354

Cited by 24 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75,76 Similar to the results of the primary efficacy analyses in patients Ն12 years old, 66 75,76 with significantly greater improvements compared with budesonide pMDI (p Ͻ 0.05) reported in patients with moderate to severe persistent asthma (Fig. 5).…”

Section: Patient-reported Outcomessupporting

confidence: 85%

“…66 -70,74 Moreover, both recommended doses of budesonide/formoterol pMDI (160/9 g and 320/9 g twice daily) have shown benefits with regard to HRQL and patient satisfaction with treatment compared with the monocomponents and placebo in adolescents and adults in patients with mild to moderate or moderate to severe persistent asthma. 66,67,75,76 Budesonide/formoterol pMDI also has shown an acceptable long-term safety profile, even at a dose twice that of the highest recommended dose (640/18 g twice daily) in patients with moderate to severe persistent asthma. 70 Budesonide/formoterol pMDI 320/9 g twice daily has shown an efficacy and tolerability profile similar to that of fluticasone propionate/salmeterol DPI 250/50 g twice daily in patients with moderate to severe persistent asthma over 7 months of treatment.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma

Korenblat¹,

Rosenwasser²

2010

allergy asthma proc

View full text Add to dashboard Cite

The combination of budesonide and formoterol administered in one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) is approved in the United States in two dosage strengths (budesonide/formoterol pMDI 80/4.5 microg x 2 inhalations [160/9 microg] or 160/4.5 microg x 2 inhalations [320/9 microg]) in a fixed-dose, twice-daily regimen for the treatment of patients > or =12 years old with persistent asthma not adequately controlled with an inhaled corticosteroid (ICS) alone. This article reviews the clinical profile of budesonide/formoterol pMDI in patients with persistent asthma, including information on pharmacogenetics, efficacy, and tolerability. Studies of budesonide/formoterol pMDI in patients with asthma were identified through PubMed and respiratory meeting abstract databases. Budesonide/formoterol pMDI 160/9 microg has shown a rapid onset (within 15 minutes) of clinically significant bronchodilation that is faster than fluticasone propionate/salmeterol dry powder inhaler (DPI) 250/50 microg (within 30 minutes). The efficacy and tolerability profile of budesonide/formoterol pMDI 320/9 microg was similar to fluticasone propionate/salmeterol DPI 250/50 microg and budesonide/formoterol DPI 320/9 microg in adults and adolescents with persistent asthma. Short-term (12-week) and long-term (6- to 12-month) studies have established greater efficacy and similar tolerability of budesonide/formoterol pMDI compared with its monocomponents and placebo in patients with mild/moderate or moderate/severe persistent asthma. Studies evaluating patient-reported outcomes, including health-related quality of life and patient satisfaction with treatment, further support the benefits of budesonide/formoterol pMDI in patients with persistent asthma. In summary, budesonide/formoterol pMDI is an effective, well-tolerated treatment option for patients with persistent asthma for whom ICS/long-acting beta2-adrenergic agonist combination therapy is appropriate.

show abstract

Section: Patient-reported Outcomessupporting

confidence: 85%

Section: Discussionmentioning

confidence: 97%

Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma

Korenblat¹,

Rosenwasser²

2010

allergy asthma proc

View full text Add to dashboard Cite

show abstract

“…In predominately white populations, significantly greater improvements in AQLQ(S) were observed with BUD/FM pMDI versus BUD pMDI in moderate to severe asthma patients (20), but the difference was not significant in mild to moderate asthma patients (21).…”

Section: Discussionmentioning

confidence: 97%

Budesonide/Formoterol Pressurized Metered-Dose Inhaler versus Budesonide: A Randomized Controlled Trial in Black Patients with Asthma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A search of the medical literature on patient preference or satisfaction with ICS/LABA therapy was conducted using PubMed, EMBASE, and ISI Web of Knowledge (Thomson Reuters), as well as a search of clinicaltrials.gov for ongoing trials, revealing overall limited information. Patient satisfaction with ICS/LABA combination therapy administered from a single inhaler was investigated in 2 randomized, double-blind, placebo-controlled, 12-week studies of budesonide/formoterol pMDI 48,49. In the first study, conducted in 405 patients with mild to moderate persistent asthma, budesonide/formoterol pMDI 160/9 μg bid was compared with budesonide pMDI 160 μg bid and formoterol DPI 9 μg bid 49.…”

Section: Ics/laba Combination Therapy: Patient Adherence Satisfactiomentioning

confidence: 99%

Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence

Murphy

Bender²

2009

JAA

Self Cite

View full text Add to dashboard Cite

Symptom control in patients with moderate to severe persistent asthma is essential to reduce the significant morbidity associated with the disease. Poor adherence to controller medications has been identified as a major contributing factor to the high level of uncontrolled asthma. This review examines patient perspectives on, and preferences for, controller medications (inhaled corticosteroid and long-acting β2-agonist combinations [ICS/LABA]), and how this may affect adherence to therapy. Fluticasone/salmeterol and budesonide/formoterol, the currently available ICS/LABA combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials. Adherence is higher with the combination ICS/LABAs than when the components are administered separately. Investigations into patient preferences for desirable attributes of asthma medications indicate that an effective reliever with a fast onset and long duration of action is preferred and may lead to improved adherence. This rapid onset of effect was perceived and highly valued in patient surveys, and was associated with greater patient satisfaction. Thus, future research should be directed at therapy that offers both anti-inflammatory activity and a rapid onset of bronchodilator effect. To further improve patient adherence and treatment outcome, the effect of these characteristics as well as other factors on adherence should also be investigated.

show abstract

The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma

Cited by 24 publications

References 26 publications

Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma

Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma

Budesonide/Formoterol Pressurized Metered-Dose Inhaler versus Budesonide: A Randomized Controlled Trial in Black Patients with Asthma

Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence

Contact Info

Product

Resources

About